Skip to content

Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis

Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06801821
Acronym
STIGMADERM
Enrollment
400
Registered
2025-01-30
Start date
2025-02-01
Completion date
2026-03-01
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Areata Alopecia, Atopic Dermatitis, Psoriasis (PsO), Vitiligo Vulgaris

Brief summary

Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis, vitiligo, and alopecia areata. * Compare the social distance and stereotyping by the general population toward individuals with facial involvement by: psoriasis, atopic dermatitis, vitiligo, and alopecia areata. * Evaluate demographic factors that describe a greater tendency toward stigmatization.

Detailed description

Basic demographic characteristics (Gender, Age, Employment status, Education level) will be recorded for each patient. Participants will be asked to observe images depicting faces of individuals with atopic dermatitis, alopecia areata, vitiligo, and psoriasis (generated through artificial intelligence systems). They will be asked to select the individual from those shown that generates the most compassion/pity, disgust, blame/disapproval/disdain, and curiosity for them, analyzing the same emotional responses investigated in a study on stigma toward psoriasis patients. In addition, each participant will be given a 14-question questionnaire on stigma (analyzing social distance and stereotyping) toward one of the four diseases under investigation (psoriasis, atopic dermatitis, vitiligo, or alopecia areata), selected randomly. For each question, responses will be expressed from 1 to 5, on a Likert scale, with lower scores indicating greater stigma. (Total score between 14 and 70)

Interventions

None listed

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* -Patients aged\>18 years, both sexes; * Signature of written informed consent;

Exclusion criteria

* Patients diagnosed with psoriasis, atopic dermatitis, vitiligo or alopecia areata. * Patients with first-degree relatives with psoriasis, atopic dermatitis, vitiligo or alopecia areata * Those who for professional or personal reasons have direct knowledge of the diseases in question.

Design outcomes

Primary

MeasureTime frameDescription
primary endopoint12 monthsCompare the percentage of patients associating the 4 different emotional reactions analyzed (compassion/pity, disgust, blame/disapproval/dislike, and curiosity) with each dermatologic condition under study.

Countries

Italy

Contacts

Primary ContactCaldarola
giacomo.caldarola@unicatt.it+390630155284

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026